Ventripoint to Exhibit VMS+ Technology at the American Society of
Echocardiography Annual Scientific Sessions
Toronto, Ontario, June 21, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they are showcasing the VMS+ 3.0 cardiac system and VMS+ Software Solution at the American Society of Echocardiography’s 30th Annual Scientific Sessions in Portland, Oregon.
Over 17,000 clinicians are members of the ASE, making it the largest global organization for cardiovascular ultrasound imaging. Members of the ASE are the leaders in setting practice standards and guidelines for the cardiac imaging field. The Scientific Sessions provide an outstanding opportunity to meet with clinicians from around the world. Ventripoint will be exhibiting at the conference in Booth #214 from June 22nd – 24th, 2019.
“The American Society of Echocardiography Annual Scientific Sessions attract industry leading clinicians and is an excellent environment to perform demonstrations of our next-generation VMS+ 3.0 system, as well as showcase the VMS+ Software Solution for the analysis of 3D Echo datasets,” commented Desmond Hirson, Ventripoint’s President.
Also, at the ASE conference the Mazankowski Heart Institute will report on its study of unreadable echocardiograms in a paper entitled “Determination of LV Volume and Ejection Fraction with a Novel 3D Knowledge Reconstruction Technique in Comparison with Contrast Echocardiography Measurements”. “The Company looks forward to the results of this independent clinical study into the potential for the VMS+ to reduce or eliminate the need for contrast injections to obtain readable heart images," Mr. Hirson stated.
Until regulatory approvals have been received, the VMS+ 3.0 system is not commercially available but is available for investigational use.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING STATEMENT:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. In particular, this news release contains forward-looking information relating to final acceptance of the Private Placement by the TSXV and the use of the proceeds therefrom. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward looking statements and information because the Corporation can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.